Published in Cancer Weekly, June 10th, 2003
According to Symbollon, the decreased loss was attributed primarily to decreased research and development expenses and decreased general and administrative expenses, partially offset by decreased revenues from product sales and decreased interest income.
In addition to other measures, "Symbollon is actively pursuing possible government sources of funding for investigation of IoGen(TM) as a potential preventative for certain types of premenopausal breast cancer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.